Analyst Price Targets — SUPN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:19 pm | — | Craig-Hallum | $65.00 | $57.58 | StreetInsider | Supernus Pharmaceuticals (SUPN) PT Raised to $65 at TD Cowen |
| December 19, 2025 12:50 pm | Annabel Samimy | Stifel Nicolaus | $55.00 | $49.28 | TheFly | Supernus price target raised to $55 from $50 at Stifel |
| October 8, 2025 11:34 pm | — | Piper Sandler | $65.00 | $48.00 | TheFly | Supernus upgraded to Overweight from Neutral at Piper Sandler |
| September 30, 2025 12:42 pm | — | Cantor Fitzgerald | $63.00 | $47.41 | TheFly | Supernus price target raised to $63 from $46 at Cantor Fitzgerald |
| August 29, 2025 10:36 am | — | Piper Sandler | $40.00 | $45.12 | TheFly | Supernus price target raised to $40 from $36 at Piper Sandler |
| July 29, 2025 8:08 pm | — | Cantor Fitzgerald | $42.00 | $33.45 | TheFly | Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald |
| September 11, 2024 4:55 am | David Amsellem | Piper Sandler | $36.00 | $33.49 | TheFly | Piper downgrades Supernus to Neutral on slower Qelbree growth |
| May 24, 2024 7:28 am | David Amsellem | Piper Sandler | $41.00 | $27.85 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN) |
| April 8, 2024 10:10 am | Irene Buhalo | Jefferies | $40.00 | $32.27 | StreetInsider | Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830' |
| April 8, 2024 10:09 am | Annabel Samimy | Stifel Nicolaus | $38.00 | $32.27 | StreetInsider | Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor' |
Latest News for SUPN
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $51.01, for a total value of $228,269.75. The sale was disclosed in a legal filing with the SEC, which can be
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.75 per share a year ago.
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SUPN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.